Roivant Sciences Quarterly Income Statement
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences revenue and earnings
In the quarter ended Jun 30, 2026, Roivant Sciences generated $1.4 million in revenue, down 33.5% from the same quarter a year earlier. Roivant Sciences reported a net loss of $189.8 million, compared with a loss of $223.4 million a year earlier. Operating margin was -25380.9%.
Diluted earnings per share came in at -$0.26.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences income statement (quarterly)
| Quarter (USD) | Q1 20262026-06-30 | Q4 20252026-03-31 | Q3 20252025-12-31 | Q2 20252025-09-30 | Q1 20252025-06-30 | Q4 20242025-03-31 | Q3 20242024-12-31 | Q2 20242024-09-30 | Q1 20242024-06-30 | Q4 20232024-03-31 | Q3 20232023-12-31 | Q2 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.44M | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M | 4.47M | 7.99M | 9.02M | 15.56M | 3.65M |
| Revenue growth (YoY) | -33.55% | -66.71% | -77.83% | -64.89% | -72.84% | -16.08% | -42.05% | +22.67% | -63.05% | — | -8.74% | -70.89% |
| Operating Expenses | 367.83M | 357.51M | 341.15M | 307.80M | 287.09M | 292.54M | 283.40M | 346.19M | 220.61M | 215.85M | 236.52M | 217.54M |
| Research & Development | 202.02M | 198.94M | 165.38M | 164.57M | 152.92M | 145.24M | 141.59M | 143.07M | 120.51M | 107.56M | 108.15M | 114.79M |
| Selling, General & Admin | — | — | — | — | — | — | — | — | 148.52M | 169.62M | 197.28M | 164.35M |
| Operating Income | -365.99M | 415.24M | -339.15M | -306.23M | -284.92M | -284.96M | -274.38M | -341.71M | -102.23M | -206.83M | 5.13B | -213.89M |
| Interest Expense | — | — | — | — | — | — | — | — | 13.40M | 7.17M | 9.44M | 9.25M |
| Other Income (Expense) | -2.13M | 12.57M | 8.34M | -5.69M | -11.21M | -2.84M | -2.82M | -1.45M | -3.61M | -11.32M | 2.11M | -1.53M |
| Pretax Income | -294.56M | 454.10M | -290.37M | -159.04M | -269.26M | -203.05M | -234.51M | -224.38M | -19.64M | -100.73M | 5.15B | -241.41M |
| Income Tax | -3.96M | 98.35M | 23.33M | 7.00M | 4.65M | 49.32M | -25.57M | 12.46M | 11.96M | -5.77M | 22.36M | 3.24M |
| Net Income | -189.84M | 302.99M | -265.89M | -113.52M | -223.35M | -206.47M | 169.38M | -230.18M | 95.30M | -151.12M | 5.10B | -304.33M |
| Net Income growth (YoY) | — | — | -256.98% | — | -334.38% | — | -96.68% | — | — | — | — | — |
| EPS (Basic) | -0.26 | 0.45 | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 | -0.31 | 0.13 | -0.04 | 6.37 | -0.40 |
| EPS (Diluted) | -0.26 | 0.34 | -0.38 | -0.17 | -0.33 | -0.28 | 0.23 | -0.31 | 0.12 | -0.02 | 6.03 | -0.40 |
| Shares Outstanding (Basic) | 720.78M | — | 696.86M | 680.95M | 680.29M | — | 722.72M | 735.47M | 735.82M | — | 800.59M | 770.23M |
| Shares Outstanding (Diluted) | 720.78M | — | 696.86M | 680.95M | 680.29M | — | 722.72M | 735.47M | 781.63M | — | 844.46M | 770.23M |
| EBITDA | -365.39M | 415.88M | -338.46M | -305.31M | -283.82M | -283.54M | -271.46M | -336.87M | -97.35M | -201.61M | 5.13B | -208.30M |
| Operating Margin | -25380.93% | 16477.78% | -16966.13% | -19492.87% | -13130.05% | -3764.40% | -3042.59% | -7636.04% | -1279.54% | -2293.06% | 32948.56% | -5863.24% |
| Net Margin | -13164.84% | 12023.57% | -13301.20% | -7225.91% | -10292.86% | -2727.54% | 1878.25% | -5143.78% | 1192.70% | -1675.33% | 32747.62% | -8342.30% |
This table shows 12 quarterly periods of Roivant Sciences's income statement, from Q1 2026 back to Q2 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ROIV's reporting calendar. What is a income statement?